Bonilla-Becerra Sandra M, de Oliveira Mariana G, Calmasini Fabiano B, Rojas-Moscoso Julio A, Zanesco Angelina, Antunes Edson
Department of Pharmacology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Faculty of Medicine, UNICASTELO, Fernandópolis, SP, Brazil.
Life Sci. 2017 Jun 15;179:120-129. doi: 10.1016/j.lfs.2017.05.006. Epub 2017 May 6.
Androgen deficiency has been implicated in urological complications of postmenopausal women. This study examined the effects of testosterone replacements on the lower urinary tract dysfunction in 4-month old ovariectomized (OVX) rats.
Sprague-Dawley female rats were OVX bilaterally. Three months later, rats received single intramuscular injections of testosterone undecanoate. Cystometric study, and bladder and urethra smooth muscle reactivities were evaluated.
Ovariectomy reduced by 65% (p<0.05) the serum testosterone levels. Testosterone replacement at 5mg/kg restored serum hormone levels to baseline, whereas 10mg/kg produced 14-fold higher testosterone levels. OVX rats exhibited significant increases of body weight, perigonadal fat and blood pressure, and reduced uterus weight, but none of these parameters were changed by testosterone replacements. OVX rats exhibited micturition dysfunction characterized by increases of basal pressure, threshold pressure, voiding frequency and post-voiding pressure. In addition, the bladder contractions induced by electrical-field stimulation (EFS) and carbachol were significantly reduced, whereas angiotensin II-induced urethral contractions were significantly increased in OVX rats. Testosterone replacement at 10mg/kg (but not at 5mg/kg) dose fully normalized the in vivo micturition dysfunction, as well as the in vitro bladder and urethral alterations. Testosterone (10mg/kg) also significantly potentiated the bladder relaxations induced by the β-adrenoceptor agonist mirabegron. The protective effects of testosterone were not modified by concomitant treatment with the aromatase inhibitor letrozole (2.5mg/kg, 4weeks).
The improvement of micturition dysfunction by testosterone replacement suggests that androgen therapy might be of therapeutic benefit for urological complications associated with post-menopause.
雄激素缺乏与绝经后女性的泌尿系统并发症有关。本研究探讨了睾酮替代对4月龄去卵巢(OVX)大鼠下尿路功能障碍的影响。
将Sprague-Dawley雌性大鼠双侧去卵巢。3个月后,大鼠单次肌肉注射十一酸睾酮。评估膀胱测压研究以及膀胱和尿道平滑肌反应性。
去卵巢使血清睾酮水平降低了65%(p<0.05)。5mg/kg的睾酮替代可使血清激素水平恢复至基线,而10mg/kg则使睾酮水平升高14倍。OVX大鼠体重、性腺周围脂肪和血压显著增加,子宫重量减轻,但这些参数均未因睾酮替代而改变。OVX大鼠表现出排尿功能障碍,其特征为基础压力、阈值压力、排尿频率和排尿后压力增加。此外,电场刺激(EFS)和卡巴胆碱诱导的膀胱收缩在OVX大鼠中显著降低,而血管紧张素II诱导的尿道收缩显著增加。10mg/kg(而非5mg/kg)剂量的睾酮替代可完全使体内排尿功能障碍以及体外膀胱和尿道改变恢复正常。睾酮(10mg/kg)还显著增强了β-肾上腺素能受体激动剂米拉贝隆诱导的膀胱舒张。睾酮的保护作用不受芳香化酶抑制剂来曲唑(2.5mg/kg,4周)联合治疗的影响。
睾酮替代改善排尿功能障碍表明雄激素治疗可能对绝经后相关的泌尿系统并发症具有治疗益处。